Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Neurogene granted options for 8,340 shares to five new employees
- ➤Options exercise price equals Neurogene’s October 5, 2026 closing share price
- ➤Awards vest over four years, subject to continued employee service
- ➤NGN-401 advances as a potential one-time Rett syndrome gene therapy
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 8,340 shares of the Company’s common stock to five new employees (the “Inducement Grants”) on October 5, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4).
Get started
Create a free account to read the full story.